Uhi Toh
Kurume, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: March 30, 2026
Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.
Journal: Breast cancer research : BCR
Published: February 02, 2026
A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026
Comprehensive genetic profiling using tissue and blood in locally advanced tumors.
Journal: Oncology reports
Published: February 04, 2025
Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study.
Journal: Breast cancer (Tokyo, Japan)
Published: February 03, 2025
A Case of Late Recurrence of Breast Cancer with Gastric Metastasis 35 Years after Surgery
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: November 21, 2024
The effective duration of systemic therapy and the neutrophil-to-lymphocyte ratio predict the surgical advantage of primary tumor resection in patients with de novo stage IV breast cancer: a retrospective study.
Journal: World journal of surgical oncology
Published: September 19, 2024
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer.
Journal: Japanese journal of clinical oncology
Published: August 05, 2024
Male Occult Primary Breast Cancer Diagnosed with Small Bowel Metastases: A Case Report.
Journal: Surgical case reports
Published: July 02, 2024
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Journal: ESMO open
Published: November 22, 2023
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Journal: Breast cancer research and treatment
Published: May 15, 2023
Last Updated: 09/26/2026